About Scientari

Intelligence Platforms

Deep, actionable analysis that helps individual practitioners make better strategic decisions — without waiting for their organization to commission a report or build an in-house solution.

Scientari builds decision infrastructure for biopharma: editorially verified market intelligence, patent-pending scoring platforms, and interactive tools that turn scattered evidence into a defensible call.

AI-Native Biotech Tracker

An editorially verified map of where AI is genuinely reshaping drug discovery.

“AI-native” has become one of the most abused labels in biopharma. The Tracker cuts through it. Every company, clinical asset, and pharma deal is held to a single, disciplined test: are learned models actually on the critical path to originating a molecule or identifying a target — or is AI merely adjacent, applied after the fact, or a marketing line grafted onto conventional chemistry?

Entries are traced to primary sources — company newsrooms, wire releases, regulatory and exchange filings, and clinical registries — rather than secondary hype, and each carries an explicit verification status so readers can see exactly how firm the evidence is.

For researchers, investors, and industry watchers, the result is a living intelligence layer that separates the companies substantively rebuilding discovery around AI from the far larger field of AI-washing, hybrid tooling plays, and repackaged pipelines. Making that call well takes hours of analyst time per name and an unusual breadth of technical fluency. Here it’s maintained continuously — and it’s free.

Explore the Tracker →

TrialReadiness™

Protocol timing review for Phase 1 and Phase 2 teams.

TrialReadiness (www.trialreadiness.com) scores the temporal design of a clinical trial protocol — whether its measurement timing actually matches the biology it’s trying to capture, benchmarked against a 275,000-trial retrospective analysis.

Trials that miss the biological window can spend years and millions producing data that can’t tell a failed drug from a failed design. TrialReadiness finds those gaps while they’re still cheap to fix, before protocol lock. Built for the teams who have to answer for the protocol.

Patent pending.

Repothesis™

<p “=””>Systematic scoring for drug repositioning candidates.

Repositioning is the source of roughly 30% of FDA approvals, yet a $35B+ opportunity that BD teams still evaluate with scattered literature and 200+ analyst hours per candidate.

Repothesis (www.repothesis.com) scores every compound-indication pair on two independent axes — scientific evidence and commercial viability — and classifies it on a decision matrix that tells a buyer which opportunities are worth pursuing. Independently graded, with no commercial conflict. The result: a defensible, board-ready repositioning call at a fraction of the time and consultant cost of a manual evaluation.

Patent pending.

Strategy Guides

We’re developing line of Strategy guides across life sciences—including topics such as drug delivery, orphan drug designation, Pre-IND planning, DNA sequencing, omics data resources and workflows, hydrogen production for data centers, and FPGA architecture. Each paired with an interactive web app that lets you explore the data, run the analysis, and apply it to your own decisions.

Every platform here rests on three decades of hands-on work in genomics data, clinical development, and pharma business development. Background →

Explore, Analyze, Decide.